-

SOPHiA GENETICS to Present at the J.P. Morgan 2023 Healthcare Conference

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS SA (NASDAQ: SOPH) today announced that Dr. Jurgi Camblong, Chief Executive Officer and Co-Founder, is scheduled to present at the J.P. Morgan 2023 Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. PST in San Francisco.

Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for two weeks following the presentation.

About SOPHiA GENETICS

SOPHiA GENETICS (NASDAQ: SOPH) is a cloud-native software company in the healthcare space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM ™ Platform, a software platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM ™ Platform and related solutions, products, and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, please visit http://www.SOPHiAGENETICS.com or follow SOPHiA GENETICS on Twitter (@SOPHiAGENETICS).

Contacts

SOPHiA GENETICS
Media Contact:
Don Granese
pr@sophiagenetics.com
or
Investor Contact:
Katherine Bailon,
ir@sophiagenetics.com

SOPHiA GENETICS

NASDAQ:SOPH

Release Versions
$Cashtags

Contacts

SOPHiA GENETICS
Media Contact:
Don Granese
pr@sophiagenetics.com
or
Investor Contact:
Katherine Bailon,
ir@sophiagenetics.com

Social Media Profiles
More News From SOPHiA GENETICS

SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Unipath Specialty Laboratory Limited, one of the leading diagnostic brands in India, is live on the SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA GENETICS’ technology, Unipath Specialty Laboratory Limited has launched HRD Gene Panel, its latest offering in the field of ca...

SOPHiA GENETICS Celebrates Swiss Biotech Award

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, was honored to accept the Swiss Biotech Success Stories Award from the Swiss Biotech Association. The Award recognizes SOPHiA GENETICS’ contributions in leading the way to democratizing data-driven medicine. Founded in Lausanne, Switzerland, SOPHiA GENETICS has been working to democratize data-driven medicine for over a de...

The University of Maryland Medical Center Chooses SOPHiA GENETICS Technology

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that the University of Maryland Medical Center (UMMC) is using SOPHiA GENETICS technology to enhance their capabilities around rare disease detection and treatment. UMMC has chosen SOPHiA Whole Exome Solution™ v2, a next-generation sequencing (NGS)-based application that provides a streamlined end-to-end wo...
Back to Newsroom